Trial · NCT05443555
Gabapentin to Reduce Alcohol and Improve Viral Load Suppression
NCT05443555, Phase 2, Active not recruiting, Boston Medical Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Gabapentin to Reduce Alcohol and Improve Viral Load Suppression. Trials, record NCT05443555. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05443555
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gabapentin to Reduce Alcohol and Improve Viral Load Suppression
- NCT number
- NCT05443555
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 220 participants, actual
- Lead sponsor
- Boston Medical Center
- Conditions
- HIV, Heavy Drinking
- Interventions
- Gabapentin, Placebo
- First posted
- 2022-07-05
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with undetectable HIV viral load | 3 months post randomization | Assessed by study test |
| Secondary | Number of participants with undetectable HIV viral load | 6 months post randomization | Assessed by study test |
| Secondary | Number of participants with undetectable HIV viral load | 12 months post randomization | Assessed by study test |
| Other | Number of heavy drinking days in the past month | 3, 6, and 12 months post randomization | Assessed by self-report using the Timeline Followback method |
| Other | Number of participants with heavy alcohol consumption defined as Phosphatidylethanol (PEth) ≥50 ng/mL | 3, 6, and 12 months post randomization | Assessed by study test |
| Other | Adherence to ART | 3, 6, and 12 months post randomization | Measured by participants' drawing a line on a Visual Analog Scale, which ranges from 0 to 100. ≥80% indicates adherence to ART. |
| Other | Percentage of ART pills taken | 3, 6, and 12 months post randomization | Assessed by self-report |
| Other | Change in pain severity from baseline to follow-up | 3, 6, and 12 months post randomization | Assessed by Brief Pain Inventory with a range of scores from 0 (none) to 10 (high) where lower scores are favorable. |
| Other | Engagement in HIV care | 3, 6, and 12 months post randomization | Defined as ≥ 1 HIV visit in the past 3 months assessed by medical record review |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AA030460 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" | SAMET, JEFFREY H.; LUNZE, KARSTEN | BOSTON MEDICAL CENTER | NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | 2022 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05443555
GET https://conductscience.org/api/trials/v1/NCT05443555/registered